AIMT News and Press, Aimmune Therapeutics Inc. From 03/16/20

Aimmune Therapeutics (NASDAQ: AIMT ) announces that the first patients in the U.S. are being treated with PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for peanut allergy. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, St...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut ( Arachis hypogaea ) ...

New data from an open-label follow-on study, ARC004 , from the 52-week PALISADE trial showed a durable treatment effect of Aimmune Therapeutics' (NASDAQ: AIMT ) Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first peanut allergy treatment approved (late January) in t...

— Additional Data Highlight PALISADE Study Patient Baseline Characteristics and Associated Treatment Response — and Improvements in Self-Reported Quality of Life Following Long-Term Treatment with PALFORZIA — Survey Results Reinforce Immunotherapy Practice Patterns...

Aimmune Therapeutics (NASDAQ: AIMT) , a biopharmaceutical company that specializes in treatments for life-threatening food allergies, reported  fourth-quarter results Thursday after the market close. Despite being down 14% at one point in Friday's trading, shares closed down only 2.5% on...

Image source: The Motley Fool. Aimmune Therapeutics Inc   (NASDAQ: AIMT) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading

Aimmune Therapeutics, Inc. (AIMT) Q4 2019 Results Earnings Conference Call February 27, 2020, 04:30 PM ET Company Participants DeDe Sheel - Vice President of Investor Relations Eric Bjerkholt - Chief Financial Officer Jayson Dallas - President and Chief Executive Officer Andrew...

Launch underway for FDA-approved PALFORZIA™, the first treatment for peanut allergy In-licensing of AIMab7195 monoclonal antibody as potential adjunctive treatment with select CODIT™ programs Pro-forma cash and investments of $443 million Webcast and confer...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March: Event: ...

Nine Abstracts Will Highlight Data Including on the First FDA-Approved Treatment for Peanut Allergy and Oral Immunotherapy Practice Implementation in a Real-World Setting Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments f...